Aclarion
Broomfield, Colorado, United States · Biotechnology, Healthcare, Health Care
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish betwe
Key facts
- Headquarters
- Broomfield, Colorado, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ACON)
- Website
- aclarion.com
- Company page
Recent activity at Aclarion
- : SEC 8-K (8.01): On April 21, 2026, Aclarion, Inc. authorized a share repurchase program allowing it to repurchase up to $2.5 million of its common stock over the next 12 months. The company plans to execute buybacks based on market conditions, using various methods such as open market purchases and privately negotiated transactions, as per Rule 10b-18 of the Securities Exchange Act of 1934. This initiative reflects the company's strategy to manage its capital structure effectively and provides flexibility to respond to market conditions. A press release was issued on April 22, 2026, announcing this authorization, emphasizing the company's commitment to shareholder value.
- : SEC 8-K (1.01): On March 19, 2026, Aclarion, Inc. entered into a stockholder rights agreement as part of a material definitive agreement adopted by its board of directors. The agreement grants one right for each outstanding share of common stock to be distributed to stockholders of record on March 30, 2026, allowing the purchase of Series D Junior Participating Preferred Stock at an exercise price of $14.00 per Right. This Rights Plan is aimed at protecting shareholder value and preventing unwanted control changes without appropriate premiums, but was not created in response to any current acquisition proposals. The implementation of these Rights is designed to give the board sufficient time to evaluate any future proposals in the best interest of shareholders.
- : SEC 8-K (7.01):
- : SEC 8-K (1.01): On January 8, 2026, Aclarion, Inc. entered into a Securities Purchase Agreement with specified purchasers to sell an aggregate of 200,000 shares of its common stock at $5.18 per share in a registered direct offering, alongside pre-funded warrants for up to 1,800,000 shares. The transaction aims to raise approximately $10.36 million before fees, with funds allocated for market development, The Clarity Trial, and other corporate purposes. The offering is set to close on January 9, 2026, contingent on customary closing conditions, and involves representations, warranties, and customary indemnification obligations from Aclarion, along with a placement fee for Dawson James Securities, Inc. as the exclusive placement agent.
- : SEC 8-K (1.01): On October 13, 2025, Aclarion, Inc. entered into a Securities Purchase Agreement to facilitate a registered direct offering of 64,000 shares of its common stock at $8.36 per share, along with pre-funded warrants for an additional 236,000 shares. The total gross proceeds from the offering are expected to be approximately $2.5 million, subject to standard closing conditions, with the offering anticipated to close on October 14, 2025. The funds will be used for market development, clinical evidence, product development, and general corporate purposes. Dawson James Securities, Inc. is serving as the exclusive placement agent, charging a fee of 7.0% of the proceeds raised.
- : SEC 8-K (1.01): On October 13, 2025, Aclarion, Inc. entered into a Securities Purchase Agreement with specified purchasers, agreeing to sell a total of 64,000 shares of its common stock at a price of $8.36 per share. Additionally, the company will grant pre-funded warrants allowing the purchase of up to 236,000 shares of common stock. This registered direct offering is expected to close on October 14, 2025, contingent upon meeting certain conditions. The transaction is significant as it provides Aclarion with immediate capital to support its operational and strategic initiatives.
- : Aclarion Appoints Greg Gould as Chief Financial Officer
- : Aclarion Announces Commercial Agreement with Scripps Health for Nociscan Technology
- : Aclarion, Inc. announces Northwestern Medicine as the inaugural site for the CLARITY trial to evaluate Nociscan's effectiveness for low back pain.
- : Aclarion
Aclarion funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2024 | Seed | $1.0M |
| Feb 2024 | Seed | $3.0M |
| May 2023 | Seed | $2.0M |
| Oct 2021 | Seed | $2.0M |
| Mar 2020 | Seed | $1.4M |
Leadership
- Brent Ness, Executive Officer, Director
- Jeffrey Lotz, Director
- David Neal, Director
- Lawrence Tannenbaum, Director
- Jeffrey Thramann, Director
- William Wesemann, Director
- Robert Eastlack, Director
- William Wesemann, Director
- David Neal, Director
- Jeffrey Lotz, Director
- Michael Harsh, Director
- Robert Eastlack, Director
Verified email and direct lines for Aclarion’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Aclarion in the news
- Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026 - Yahoo! Finance Canada (Oct 20, 2026)
- Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs - The Manila Times (Oct 22, 2026)
- Aclarion to Present at the 20th Annual LD Micro Main Event - Yahoo Finance (Oct 13, 2026)
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment - Yahoo Finance (Oct 08, 2026)
- Channel 4’s Dirty Business is a clarion call to nationalise the water industry - The Guardian (Feb 23, 2026)
- Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site - Yahoo Finance (Aug 20, 2026)
- A Clarion Call for Public Health: Sustain Non-Partisan Federal Service - Petrie-Flom Center (Jul 17, 2025)
- Opinion | A Clarion Call for Rearmament - WSJ (Jun 02, 2024)
Companies similar to Aclarion
- Venus Concept Inc. · Biotechnology, Healthcare, Health Care, Other
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care
- ReCode Therapeutics · Biotechnology, Healthcare, Health Care
- iSpecimen · Biotechnology, Healthcare, Health Care
About Aclarion: questions and answers
What does Aclarion do?
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish betwe
Where is Aclarion headquartered?
Aclarion is headquartered in Broomfield, Colorado, United States.
Has Aclarion raised funding?
Yes. Fundz has recorded 5 funding events for Aclarion. The most recent, Seed of $1.0M, was in Oct 2024.
What is the latest news on Aclarion?
On Apr 22, 2026, SEC 8-K (8.01): On April 21, 2026, Aclarion, Inc. authorized a share repurchase program allowing it to repurchase up to $2.5 million of its common stock over the next 12 months. The company plans to execute buybacks based on market conditions, using various methods such as open market purchases and
Is Aclarion a public company?
Yes. Aclarion is publicly traded under the ticker ACON.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy